We think the strategy to find more effective combination therapies in hematology and build a larger oncology and dermatology portfolio is solid, although we're waiting for key data before assuming the ...
Here's our initial take on Vertex Pharmaceuticals' (NASDAQ: VRTX) fourth-quarter financial report. Key Metrics Metric Q4 2023 Q4 2024 Change vs. Expectations Revenue $2.52 billion $2.91 billion 16% ...
6d
Eli Lilly's innovative culture and strong financial commitment to developing the next generation of drugs set the company apart from its peers and fuel its long-term growth. Lilly holds ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback